生命科学资讯

Is 10x Genomics (TXG) Using PharosAI’s NHS Partnership To Quietly Recast Its Spatial Biology Moat? - simplywall.st

Is Illumina’s (ILMN) Clinical Consumables Surge Quietly Redefining Its Core Investment Story? - Yahoo Finance UK

Assessing Illumina (ILMN) Valuation After Recent Share Price Weakness And Mixed Long Term Returns - simplywall.st

Lonza’s Strategic Pivot Fuels Robust Growth and Shareholder Returns - AD HOC NEWS

Hims cancels plans to sell compounded GLP-1 pill after FDA backlash

Hims says it will stop selling GLP-1 pill, after legal pressure from US

#ACTRIMS26: Sanofi unpacks data from a failed Phase 3 tolebrutinib trial in PPMS

Taking A Fresh Look At Thermo Fisher Scientific (TMO) Valuation After Recent Share Price Weakness - simplywall.st

Agilent’s SLAS2026 Automation Push Might Change The Case For Investing In Agilent Technologies (A) - simplywall.st

The Hims vs. Novo showdown; Pfizer’s monthly GLP-1 data; Q4 earnings roundup; and more

Lonza Issues Partially Unreadable Release, Leaving Details Unclear - TipRanks

Illumina (ILMN) One Off Gain Shapes Profitability Narrative After FY 2025 Earnings - simplywall.st

Illumina Earnings Call Highlights Clinical Growth Momentum - TipRanks

US calls for DOJ investigation of Hims over GLP-1 drugs

AGILENT TECHNOLOGIES, INC. ($A) CEO 2025 Pay Revealed - Quiver Quantitative

TrumpRx launch falls flat for some, citing generic access

A - Agilent Technologies Inc Stock Price and Quote - Finviz

Key facts: Illumina Q4 2025 revenue rises to $1.16B; 2026 growth forecasted - TradingView

UniQure pauses Fabry gene therapy dosing in 2 groups after toxicities emerge

Roche’s Genentech cut at least 489 jobs last year, new disclosure reveals